 |
0 Diseases |  |
24 Trials |
|
24 Trials |  |
921 News |  |
| «12345678910111213...1920» |
- Rybelsus (semaglutide oral) / Novo Nordisk
Symposium - Oral Semaglutide for Treatment of Obesity and Type 2 Diabetes (Ballroom 20ABC) - Apr 10, 2023 - Abstract #ADA2023ADA_2131;
- Victoza (liraglutide) / Novo Nordisk, Rybelsus (semaglutide oral) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk
An Indirect Treatment Comparison of the Cardiovascular Protective Effect of Semaglutide vs. Liraglutide in Subjects with Type 2 Diabetes (Poster Halls B-C; [Board No. 790]) - Apr 10, 2023 - Abstract #ADA2023ADA_1380;
The results demonstrated a risk reduction of CV events (3P-MACE) for semaglutide vs liraglutide of 22-27% depending on the population studied. These results may have implications for clinical practice.
- Rybelsus (semaglutide oral) / Novo Nordisk
Glucose and Weight Outcomes Associated with Oral Semaglutide in the Real-World (Poster Halls B-C; [Board No. 787]) - Apr 10, 2023 - Abstract #ADA2023ADA_1377;
The numbers achieving a HbA1c?7.5% also increased. In the light of this, further data collection and analysis should be undertaken, including comparisons between oral and injectable GLP1-RAs and analysis of switches between them
- metformin / Generic mfg.
Occurrence of Gastrointestinal (GI) Side Effects upon GLP-1 Receptor Agonist (GLP-1RA) Initiation with Concomitant Metformin Use (Poster Halls B-C; [Board No. 780]) - Apr 10, 2023 - Abstract #ADA2023ADA_1369;
The percent of participants who developed new or serious GI adverse events during the titration period was similar across those with or without concomitant metformin use in each group (GLP-1RA or placebo) in all trials (Table). The occurrence of individual GI event (nausea, vomiting, diarrhea, and constipation) was also similar (data not shown).In summary, concomitant metformin use does not increase the occurrence of GI symptoms during early GLP-1RA treatment.
- | Rybelsus (semaglutide oral) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Retrospective data, Journal: Semaglutide reduces risk of MACE consistently across baseline triglyceride levels in patients with type 2 diabetes: Post Hoc Analyses of SUSTAIN 6 and PIONEER 6 trials. (Pubmed Central) - Apr 5, 2023
The occurrence of individual GI event (nausea, vomiting, diarrhea, and constipation) was also similar (data not shown).In summary, concomitant metformin use does not increase the occurrence of GI symptoms during early GLP-1RA treatment. No abstract available
- ||| Rybelsus (semaglutide oral) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk
P1/2 data, P3 data, Journal: Safety and tolerability of semaglutide across the SUSTAIN and PIONEER phase IIIa clinical trial programmes. (Pubmed Central) - Apr 4, 2023
The most common AEs with semaglutide were gastrointestinal disorders, which decreased with continued therapy. These comprehensive safety/tolerability data may better inform patient selection and guidance in care.
- || Rybelsus (semaglutide oral) / Novo Nordisk
Trial initiation date: Regulatory Post Marketing Surveillance (rPMS) Study of Rybelsus (Oral Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea (clinicaltrials.gov) - Apr 4, 2023
P=N/A, N=600, Not yet recruiting, Sponsor: Novo Nordisk A/S
These comprehensive safety/tolerability data may better inform patient selection and guidance in care. Initiation date: Jan 2023 --> Dec 2024
- ||| Rybelsus (semaglutide oral) / Novo Nordisk
Enrollment open: A Research Study to Compare How Much Semaglutide is Found in the Blood With Different Tablets of Oral Semaglutide in Healthy Participants (clinicaltrials.gov) - Mar 31, 2023
P1, N=260, Recruiting, Sponsor: Novo Nordisk A/S
Initiation date: Jan 2023 --> Dec 2024 Not yet recruiting --> Recruiting
- ||| Rybelsus (semaglutide oral) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk, Mounjaro (tirzepatide) / Eli Lilly
Can you lose weight on Ozempic semaglutide mounjaro without exercise? #Ozempic #mounjaro #wegovy #semaglutide #rybelsus (Twitter) - Mar 30, 2023
- ||| Rybelsus (semaglutide oral) / Novo Nordisk
Trial completion, Real-world evidence, Real-world: PIONEER REAL: A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Japan, as Part of Local Clinical Practice (clinicaltrials.gov) - Mar 30, 2023
P=N/A, N=650, Completed, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Enrolling by invitation --> Completed
- ||||||| Rybelsus (semaglutide oral) / Novo Nordisk
Trial completion, Enrollment change: PIONEER PLUS: Research Study to Compare Three Doses of Semaglutide Tablets Taken Once Daily in People With Type 2 Diabetes (clinicaltrials.gov) - Mar 30, 2023
P3, N=1606, Completed, Sponsor: Novo Nordisk A/S
Enrolling by invitation --> Completed Active, not recruiting --> Completed | N=1224 --> 1606
- ||| Rybelsus (semaglutide oral) / Novo Nordisk
Trial completion, Real-world evidence, Real-world: PIONEER REAL: A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Sweden, as Part of Local Clinical Practice (clinicaltrials.gov) - Mar 30, 2023
P=N/A, N=194, Completed, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed | N=1224 --> 1606 Enrolling by invitation --> Completed
- || Rybelsus (semaglutide oral) / Novo Nordisk
Novo Nordisk's high-dose Rybelsus win tees up regulatory filings—and new rivalries @FiercePharma https://t.co/tsyPmLw1bf (Twitter) - Mar 28, 2023
- ||||| Rybelsus (semaglutide oral) / Novo Nordisk
Oral semaglutide CV outcomes in T2DM w/eASCVD &/or CKD: SOUL baseline characteristics… Interesting ➡️ 26.7% on SGLT2i ➡️ quarter with HF ➡️ limb ischaemia part of 2ndry outcome ➡️exploratory outcomes include cognitive scores https://t.co/DPMBns7tIr @kamleshkhunti @DLBHATTMD (Twitter) - Mar 28, 2023
- | Rybelsus (semaglutide oral) / Novo Nordisk
Gracias Cristobal SEMAGLUTIDE Oral Buenos números. Usted decide cuál usar HBA1C 14. 25 50 mg disminuye. 1.5% 1.9. 2.2 =Glucosa 45. 57. 66 mg/dl PESO. 4.5. 7. 9.2 @magraziagirone @TatianaLandetta (Twitter) - Mar 24, 2023
- ||| Rybelsus (semaglutide oral) / Novo Nordisk
New P1 trial: A Research Study to Compare How Much Semaglutide is Found in the Blood With Different Tablets of Oral Semaglutide in Healthy Participants (clinicaltrials.gov) - Mar 24, 2023
P1, N=260, Not yet recruiting, Sponsor: Novo Nordisk A/S
- |||| Rybelsus (semaglutide oral) / Novo Nordisk
Enrollment open, Trial initiation date: ASCEND PLUS: A Study of Cardiovascular Events iN Diabetes Plus (clinicaltrials.gov) - Mar 17, 2023
P4, N=20000, Recruiting, Sponsor: University of Oxford
Enrolling by invitation --> Completed Not yet recruiting --> Recruiting | Initiation date: Dec 2022 --> Mar 2023
- |||| lotiglipron (PF-07081532) / Pfizer
Enrollment open, Enrollment change: Trial to Learn About the Study Medicine (PF-07081532) and Rybelsus in People With Type 2 Diabetes and Separately PF-07081532 in People With Obesity (clinicaltrials.gov) - Mar 13, 2023
P2, N=780, Recruiting, Sponsor: Pfizer
Not yet recruiting --> Recruiting | Initiation date: Dec 2022 --> Mar 2023 Active, not recruiting --> Recruiting | N=337 --> 780
- Rybelsus (semaglutide oral) / Novo Nordisk
Medication Utilization Patterns Among T2DM Patients Initiating Treatment with Oral Semaglutide () - Mar 9, 2023 - Abstract #ISPOR2023ISPOR_2158;
MET was a common concomitant T2DM prescription among patients initiating oral sema. This real-world exploratory study may help physicians and payers understand clinical behavior within the first 6 months of oral sema use.
- ||| Rybelsus (semaglutide oral) / Novo Nordisk
Retrospective data, Journal, Adverse events: Body weight loss with oral semaglutide is mediated predominantly by effects other than gastrointestinal adverse events in patients with type 2 diabetes: a post hoc analysis. (Pubmed Central) - Mar 7, 2023
This real-world exploratory study may help physicians and payers understand clinical behavior within the first 6 months of oral sema use. No abstract available
- |||||| Rybelsus (semaglutide oral) / Novo Nordisk
New trial, Real-world evidence, Patient reported outcomes, Real-world: DOORS: A Research Study to Understand How Oral Semaglutide Works in People With Type 2 Diabetes Who Change From Dipeptidyl Peptidase-4 Inhibitor (DPP4i) Treatment to Oral Semaglutide in Italy (clinicaltrials.gov) - Mar 6, 2023
P=N/A, N=390, Enrolling by invitation, Sponsor: Novo Nordisk A/S
- ||| lotiglipron (PF-07081532) / Pfizer
Enrollment closed, Enrollment change: Trial to Learn About the Study Medicine (PF-07081532) and Rybelsus in People With Type 2 Diabetes and Separately PF-07081532 in People With Obesity (clinicaltrials.gov) - Mar 6, 2023
P2, N=337, Active, not recruiting, Sponsor: Pfizer
No abstract available Recruiting --> Active, not recruiting | N=780 --> 337
- ||| Rybelsus (semaglutide oral) / Novo Nordisk
Enrollment open: O-SEMA-Fast: A Research Study to Understand How Oral Semaglutide Works in People With Type 2 Diabetes Who Plan to Fast During Ramadan in the United Arab Emirates, Saudi Arabia, and Kuwait (clinicaltrials.gov) - Mar 3, 2023
P=N/A, N=288, Enrolling by invitation, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting | N=780 --> 337 Not yet recruiting --> Enrolling by invitation
- | Rybelsus (semaglutide oral) / Novo Nordisk, Mounjaro (tirzepatide) / Eli Lilly
New P1/2 trial, Metastases: Effect on Non-Alcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus With Gastric Inhibitory Polypeptide/Glucagon Like Peptide-1 Analogue (clinicaltrials.gov) - Mar 2, 2023
P1/2, N=30, Not yet recruiting, Sponsor: Dr Adnan Agha
- | Rybelsus (semaglutide oral) / Novo Nordisk
Trial completion: The Effect of Semaglutide on Pituitary Function (clinicaltrials.gov) - Feb 22, 2023
P4, N=10, Completed, Sponsor: University of Tartu
Not yet recruiting --> Enrolling by invitation Not yet recruiting --> Completed
- || Rybelsus (semaglutide oral) / Novo Nordisk
Truly?? Do you have a reference? I’ve asked MSL and they said only 14 mg for rybelsus is being tested (Twitter) - Feb 17, 2023
- |||| Rybelsus (semaglutide oral) / Novo Nordisk
🔎 ACG Case Reports Journal 🔍 Progressive Cholestasis and Biliary Cirrhosis After Initiating Oral Semaglutide Ma, et al. 👉 https://t.co/Ejl0vU7TIR @nagachalasani @rajVuppaLanchi @NickMcDonaldMD @SempokuyaMD (Twitter) - Feb 10, 2023
- |||||| Rybelsus (semaglutide oral) / Novo Nordisk
New trial: O-SEMA-Fast: A Research Study to Understand How Oral Semaglutide Works in People With Type 2 Diabetes Who Plan to Fast During Ramadan in the United Arab Emirates, Saudi Arabia, and Kuwait (clinicaltrials.gov) - Feb 8, 2023
P=N/A, N=288, Not yet recruiting, Sponsor: Novo Nordisk A/S
- |||||| Rybelsus (semaglutide oral) / Novo Nordisk
New trial: Regulatory Post Marketing Surveillance (rPMS) Study of Rybelsus (Oral Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea (clinicaltrials.gov) - Feb 6, 2023
P=N/A, N=600, Not yet recruiting, Sponsor: Novo Nordisk A/S
- | Rybelsus (semaglutide oral) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Retrospective data, Journal: Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared to placebo. (Pubmed Central) - Feb 5, 2023
Hazard ratios (semaglutide versus placebo) for time to persistent eGFR decline were significantly under 1.0 for all eGFR thresholds in the overall population; and were numerically lower in the baseline eGFR 30 to under 60 mL/min/1.73 m subgroup versus the overall population, although no significant interaction was observed for treatment effect by subgroup. Thus, pooled analyses of clinical trial data in patients with T2D suggest that semaglutide may reduce the rate of eGFR decline.
- |||| Rybelsus (semaglutide oral) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Clinical, Retrospective data: Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared to placebo @KatherineTuttl8 https://t.co/ihG4WsvVSO (Twitter) - Feb 3, 2023
- | Rybelsus (semaglutide oral) / Novo Nordisk
New P4 trial: Sema-RTx: Semaglutide Treatment for Hyperglycaemia After Renal Transplantation (clinicaltrials.gov) - Jan 27, 2023
P4, N=104, Not yet recruiting, Sponsor: Rigshospitalet, Denmark
- ||| Rybelsus (semaglutide oral) / Novo Nordisk
Trial completion, Real-world evidence, Real-world: PIONEER REAL: A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in The Netherlands, as Part of Local Clinical Practice (clinicaltrials.gov) - Jan 26, 2023
P=N/A, N=145, Completed, Sponsor: Novo Nordisk A/S
Thus, pooled analyses of clinical trial data in patients with T2D suggest that semaglutide may reduce the rate of eGFR decline. Active, not recruiting --> Completed
- ||| Rybelsus (semaglutide oral) / Novo Nordisk
Trial completion, Real-world evidence, Real-world: PIONEER REAL: A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Switzerland, as Part of Local Clinical Practice (clinicaltrials.gov) - Jan 26, 2023
P=N/A, N=194, Completed, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||| Rybelsus (semaglutide oral) / Novo Nordisk
Enrollment closed, Trial primary completion date: OASIS 4: Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in People Who Have a Body Weight Above the Healthy Range (clinicaltrials.gov) - Jan 25, 2023
P3, N=281, Active, not recruiting, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2022 --> Mar 2024
- || Rybelsus (semaglutide oral) / Novo Nordisk
Review, Journal: First-in-Class Oral Semaglutide: Overcoming Barriers of Incretinisation in the Indian Context. (Pubmed Central) - Jan 10, 2023
However, subcutaneous treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is limited by their injectable mode of administration. The present review highlights barriers to incretinisation with GLP-1RAs and the role of first-in-class oral semaglutide in the Indian context and provides guidance to physicians on its initiation and uses.
- || Review, Journal: An update on peptide-based therapies for type 2 diabetes and obesity. (Pubmed Central) - Jan 8, 2023
Particularly high efficacy in both glucose- and weight lowering capacities has also been observed with the GLP-1R/GIP-R unimolecular dual agonist, tirzepatide...Other pharmacological approaches to chronic weight management include the human monoclonal antibody, bimagrumab which blocks activin type II receptors and is associated with growth of skeletal muscle, an antibody blocking activation of GIPR to which are conjugated GLP-1R peptide agonists (AMG-133), and the melanocortin-4 receptor agonist, setmelanotide for use in certain inherited obesity conditions. The high global demand for the GLP-1R agonists liraglutide and semaglutide as anti-obesity agents has led to shortage so that their use in T2D therapy is currently being prioritized.
- Rybelsus (semaglutide oral) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk, Trulicity (dulaglutide) / Eli Lilly
COMPARING PRESCRIPTION TRENDS FOR ORAL AND SUBCUTANEOUS GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS (GLP-1 RA) IN THE UNITED STATES (Poster Hall_Hall F) - Jan 4, 2023 - Abstract #ACCWCC2023ACC_WCC_6163;
Its limited uptake may be due to several factors, including the paucity of data on its cardiorenal and weight loss benefits relative to older GLP-1RAs. It remains to be seen how the upcoming SOUL clinical trial influences adoption of oral semaglutide.
- || Rybelsus (semaglutide oral) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Cost of Ozempic and Rybelsus 14mg for 1 month in Switzerland is almost identical: 130 CHF which equals almost exatly 130 USD. I know that you guys have interesting drug prices over there, but 1300? 🤯 (Twitter) - Jan 3, 2023
- || Rybelsus (semaglutide oral) / Novo Nordisk, NNC0385-0434 / Novo Nordisk
Trial primary completion date: A Research Study Looking at New Protein-based Tablets in Healthy Male Participants (clinicaltrials.gov) - Dec 28, 2022
P1, N=384, Recruiting, Sponsor: Novo Nordisk A/S
It remains to be seen how the upcoming SOUL clinical trial influences adoption of oral semaglutide. Trial primary completion date: Nov 2022 --> Feb 2023
- || Rybelsus (semaglutide oral) / Novo Nordisk, Trulicity (dulaglutide) / Eli Lilly
Retrospective data, Review, Journal: Association of glucagon-like peptide-1 receptor agonists with cardiac arrhythmias in patients with type 2 diabetes or obesity: a systematic review and meta-analysis of randomized controlled trials. (Pubmed Central) - Dec 27, 2022
GLP-1 RAs therapy was not associated with an overall higher risk of arrhythmias, demonstrating an assuring cardiovascular safety profile. Further studies are required to determine whether the potential antiarrhythmic or arrhythmogenic effect of GLP-1 RAs is drug-specific and varies from doses or baseline BMI.
- || Rybelsus (semaglutide oral) / Novo Nordisk, Mycapssa (octreotide) / Amryt
Review, Journal: Gastrointestinal Permeation Enhancers for the Development of Oral Peptide Pharmaceuticals. (Pubmed Central) - Dec 24, 2022
Sodium salcaprozate (SNAC) and sodium caprylate (C8) have been used as gastrointestinal permeation enhancers for semaglutide and octreotide, respectively. Herein, we briefly review two approved products, Rybelsus and Mycapssa, and discuss the permeation properties of SNAC and medium chain fatty acids, sodium caprate (C10) and C8, focusing on Eligen technology using SNAC, TPE technology using C8, and gastrointestinal permeation enhancement technology (GIPET) using C10.
- Rybelsus (semaglutide oral) / Novo Nordisk
EXPLORING THE ROLE OF NEUROINFLAMMATION AND RELATED PATHWAYS ON THE EFFECTS OF SEMAGLUTIDE IN ALZHEIMER'S DISEASE: BIOMARKER ANALYSES IN EVOKE/EVOKE+ (EXHIBITION) - Dec 23, 2022 - Abstract #ADPD2023ADPD_1480;
P3
Plasma biomarkers will be measured in all participants (except those in Chi na) of the phase III randomized, placebo -controlled evoke/evoke+ trials (N=1840 per trial) (NCT04777396 and NCT04777409) studying oral semaglutide 14 mg once daily in early AD... The evoke/evoke+ program is collecting a large repertoire of biomarkers to document the biological impact of semaglutide, provide evidence of disease modification, and aid understanding of the relationship between neuroinflammation and neurodegeneration in early AD.
- | Rybelsus (semaglutide oral) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Retrospective data, Journal: Hemoglobin A1c Reduction With the GLP-1 Receptor Agonist Semaglutide Is Independent of Baseline eGFR: post hoc Analysis of the SUSTAIN and PIONEER Programs. (Pubmed Central) - Dec 20, 2022
This post hoc analysis assessed the HbA1c-lowering efficacy of semaglutide, a GLP-1RA, in participants with a range of kidney functions in the SUSTAIN 4-6 and 10 (subcutaneous semaglutide) and PIONEER 5 and 6 (oral semaglutide) clinical trials...No new safety concerns with semaglutide were identified. The HbA1c-lowering effect of semaglutide in participants with T2D was comparable irrespective of eGFR, which ranged upwards from eGFR >15 ml/min per 1.73 m.
- || Rybelsus (semaglutide oral) / Novo Nordisk
Enrollment status, Real-world evidence, Real-world: PIONEER REAL: A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Italy, as Part of Local Clinical Practice (clinicaltrials.gov) - Dec 19, 2022
P=N/A, N=462, Enrolling by invitation, Sponsor: Novo Nordisk A/S
The HbA1c-lowering effect of semaglutide in participants with T2D was comparable irrespective of eGFR, which ranged upwards from eGFR >15 ml/min per 1.73 m. Recruiting --> Enrolling by invitation
- |||| Rybelsus (semaglutide oral) / Novo Nordisk
Trial primary completion date: A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE) (clinicaltrials.gov) - Dec 8, 2022
P3, N=1840, Recruiting, Sponsor: Novo Nordisk A/S
Recruiting --> Enrolling by invitation Trial primary completion date: Aug 2024 --> Sep 2025
- |||| Rybelsus (semaglutide oral) / Novo Nordisk
Trial completion date, Trial primary completion date: A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus) (clinicaltrials.gov) - Dec 8, 2022
P3, N=1840, Recruiting, Sponsor: Novo Nordisk A/S
Trial primary completion date: Aug 2024 --> Sep 2025 Trial completion date: Apr 2027 --> Oct 2026 | Trial primary completion date: Aug 2024 --> Sep 2025
- ||| Rybelsus (semaglutide oral) / Novo Nordisk
Trial completion date: A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE) (clinicaltrials.gov) - Dec 6, 2022
P3, N=1840, Recruiting, Sponsor: Novo Nordisk A/S
Trial completion date: Apr 2027 --> Oct 2026 | Trial primary completion date: Aug 2024 --> Sep 2025 Trial completion date: Apr 2026 --> Oct 2026
- || Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Trial completion date, Trial primary completion date: Epidemiological Assessment of the Risk for Pancreatic Cancer Associated With the Use of Semaglutide in Patients With Type 2 Diabetes - A Cohort Study Based on Nordic Registry Data (clinicaltrials.gov) - Dec 2, 2022
P=N/A, N=600000, Enrolling by invitation, Sponsor: Novo Nordisk A/S
Trial completion date: Apr 2026 --> Oct 2026 Trial completion date: Aug 2024 --> Dec 2024 | Trial primary completion date: Aug 2024 --> Dec 2024
- || Rybelsus (semaglutide oral) / Novo Nordisk
Review, Journal: HOW DID GLP-1RAs BRING ABOUT A PARADIGM SHIFT IN THE GUIDELINES OF MANAGING T2DM: A PATH TO GLUCO-CARDIO CENTRICITY: Oral Semaglutide. (Pubmed Central) - Nov 27, 2022
As an adjunct to metformin or ongoing therapy, GLP1RAs or sodium-glucose cotransporter-2 inhibitors are recommended by the American Diabetes Association and the European Association for the Study of Diabetes (EASD). Thus, this review summarises GLP-1RA and their significance in the paradigm shift in diabetes care recommendations from glucocentric to gluco-cardiocentric.